Alzheimer?s Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million Americans. Despite significant investment in drug discovery and development, no therapeutic options yet exist that can prevent, slow, or cure AD. The Accelerating Medicines Partnership in Alzheimer?s Disease Target Discovery and Preclinical Validation project (AMP-AD) was designed to help address this problem by identifying candidate targets through evaluation of AD-induced changes in human molecular state on a systems level. The AMP-AD Data Coordination Center (DCC) manages and distributes AMP-AD data assets in accordance with the FAIR principles in order to support the open science principles of the AMP-AD program. Data assets are distributed through the AD Knowledge Portal, an NIH-designated repository that serves to support the NIA?s strategic goal to propagate data sharing under FAIR principles and to promote open science. This supplement is designed to extend the functionality of the DCC to meet the emerging needs and opportunities enabled by recent expansions in the scale and scope of the AMP-AD data ecosystem including through the initiation of AMP-AD 2.0. The supplement will extend the scale of the data ecosystem by increasing data ingress capacity to support data contributors in rapid data annotation, validation and upload. It will also ensure interoperability between high value AMP-AD data assets, particularly between AMP-AD 1.0 and 2.0, by ensuring that they are harmoniously processed to meet current analysis standards.
AD is a universally fatal disease for which no disease-modifying therapies have been successfully brought to market. The Accelerating Medicines Partnership in Alzheimer?s Disease Target Discovery and Preclinical Validation project (AMP-AD) is working to use systems biology approaches to identify candidate targets with potential therapeutic impact. By creating a scalable and interoperable open research ecosystem, the AMP-AD data coordinating center ensures broad use of these high-value data assets and supports the evaluation of candidate targets from a wide array of experts and research domains across the broad research community.
